Key Insights on Gross Profit: GSK plc vs United Therapeutics Corporation

GSK vs United Therapeutics: A Decade of Financial Growth

__timestampGSK plcUnited Therapeutics Corporation
Wednesday, January 1, 2014156830000001162636000
Thursday, January 1, 2015150700000001396725000
Friday, January 1, 2016185990000001526100000
Sunday, January 1, 2017198440000001619600000
Monday, January 1, 2018205800000001429100000
Tuesday, January 1, 2019218910000001331200000
Wednesday, January 1, 2020223950000001375200000
Friday, January 1, 2021225110000001563000000
Saturday, January 1, 2022197700000001789600000
Sunday, January 1, 2023217630000002070000000
Loading chart...

Unleashing insights

A Tale of Two Giants: GSK plc vs United Therapeutics Corporation

In the ever-evolving pharmaceutical industry, the financial health of companies is a key indicator of their market prowess. Over the past decade, GSK plc and United Therapeutics Corporation have showcased contrasting trajectories in gross profit. From 2014 to 2023, GSK plc consistently outperformed, with gross profits peaking at approximately $22.5 billion in 2021, marking a 43% increase from 2014. In contrast, United Therapeutics Corporation, while smaller in scale, demonstrated a steady growth, achieving a 78% rise in gross profit, reaching around $2.07 billion by 2023. This growth underscores the company's strategic advancements in niche markets. As the pharmaceutical landscape continues to shift, these financial insights provide a glimpse into the strategic maneuvers and market positioning of these industry titans.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025